Terns Pharma successfully shifted its focus after its GLP-1 obesity drug showed underwhelming results. By pivoting to its promising oncology asset for chronic myeloid leukemia, the company dramatically increased its value, culminating in a nearly $7 billion acquisition by Merck. This demonstrates the value of decisively abandoning struggling programs for high-potential ones.

Contrary to seeking fully de-risked assets, pharmaceutical companies often prefer acquiring companies with some remaining clinical risk. This strategy allows them to leverage unique insights on early data to acquire assets at a better valuation, creating an opportunity for outsized returns before the value is obvious to others.

NervGen is expanding its drug's potential by partnering with the Department of Defense. Walter Reed tests it for traumatic brain injury, and the Air Force for hearing loss. This strategy provides non-dilutive funding and validation for new indications, broadening the company's platform with minimal internal R&D spend.

Neurvati's model bypasses early-stage discovery risk by requiring assets to have 'peri-proof-of-concept' data (e.g., Phase 1b/2a) in humans. This focus on clinically de-risked programs with demonstrated biological activity and safety allows them to concentrate on late-stage development and execution.

Instead of relying on finding novel targets, a key strategy in neuropsychiatry is to revisit failed compounds that showed efficacy signals. Companies use modern chemistry and delivery to engineer solutions that separate efficacy from the historical liabilities that halted development, turning past failures into new opportunities.

The GSK3 inhibitor was developed for CNS diseases, requiring high specificity and the ability to cross the blood-brain barrier. These same pharmaceutical characteristics—potency and lipophilicity—proved highly advantageous for treating cancer, demonstrating an unexpected but effective therapeutic pivot from neuroscience to oncology.

Neurocrine mitigates the high risk of its late-stage psychiatry programs, which have uncertain outcomes until Phase 3, by investing in an obesity asset. This program offers the ability to see clear efficacy signals in early Phase 1B trials, providing faster data for decision-making and balancing portfolio risk and cost.

Tortugas Neuroscience's startup strategy focuses on in-licensing new chemical entities that have already cleared Phase 1, bypassing early toxicity and IND risks. Their criteria demand that each asset be extensible to multiple indications within CNS, creating operating leverage and maximizing the chances of success.

While new technology is a factor, renewed investment in neuroscience is heavily driven by its "greenfield" status. Unlike crowded markets like oncology, many neurological disorders lack effective treatments, offering significant, untapped commercial potential for large pharmaceutical companies seeking new growth areas.